Skip to main
IGC
IGC logo

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. is positioned favorably due to its innovative investigational drug assets targeting Alzheimer's disease, which have shown potential efficacy in suppressing key hallmarks of the condition. The company's current valuation presents an attractive opportunity, as evidenced by an increased Net Present Value (NPV) analysis projecting significant upside from the prevailing share price. Furthermore, the anticipation of additional positive data from ongoing studies serves as a potential catalyst for further stock performance enhancement.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million, with earnings per share (EPS) of $(0.02), aligning with consensus estimates but indicating a lack of profitability. The company's focus on developing investigational drugs for Alzheimer's disease presents substantial risks, including potential failures in demonstrating safety and efficacy, along with obtaining necessary regulatory approvals. Additionally, the company faces liquidity and balance sheet risks, heightened competition, and shifting investor sentiment towards biotech stocks, all contributing to a negative outlook on its financial stability and growth potential.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.